Home Biosimilar Antibodies Others Others Lampalizumab (Anti-Complement Factor D)
For research use only. Not for use in humans.

Lampalizumab (Anti-Complement Factor D)

Synonyms: CFD， Adipsin

Lampalizumab (Anti-Complement Factor D) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research. MW: 145.5 KD.

Lampalizumab (Anti-Complement Factor D)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Mechanism of Action

Description
Lampalizumab (Anti-Complement Factor D) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research. MW: 145.5 KD.

Product Details

CAS No. 1278466-20-8
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02745119 TERMINATED Drug: Lampalizumab Geographic Atrophy Hoffmann-La Roche 2016-07-21 PHASE3
NCT02247479 TERMINATED Drug: Lampalizumab Geographic Atrophy Hoffmann-La Roche 2014-09-18 PHASE3
NCT02247531 TERMINATED Drug: Lampalizumab Geographic Atrophy Hoffmann-La Roche 2014-10-06 PHASE3
NCT01602120 TERMINATED Drug: Lampalizumab Geographic Atrophy Genentech, Inc. 2012-05-29 PHASE2
NCT02288559 COMPLETED Drug: Lampalizumab Geographic Atrophy Genentech, Inc. 2015-03-30 PHASE2

(data from https://clinicaltrials.gov, updated on 2019-03-06)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.